Chinese researchers have developed AI-driven system that could diagnose cancer. A particular kind of prostate cancer may be identified using the artificial intelligence system.
The cancer diagnosis is the single most difficult factor of this treatment. The research report suggests that the accuracy of the system is as high as any behavioral evaluation. The machine can remove the lack of trained pathologists in the world.
The scientists from China are positioning the machine as something which can be used to streamline and remove the variation in cancer diagnosis process. The additional advancements from the AI algorithm can lead to automated or partially-automated prostate cancer identification.
The system presented by researchers shows similar levels of precision as an individual pathologist.
The lead scientist, Hongqian Guo said, "This really is not going to replace an individual pathologist. We require an experienced pathologist to take accountability for your final diagnosis. What it can do is help pathologists get better, quicker diagnosis, in addition to eliminating the daily variation in judgment that may creep into human tests."
The researchers have fed the information of 918 prostate whole bracket pathology trials from 283 patients in the computer system. The machine was conducted through the analysis, which the algorithm is gradually learning and improving the identification.
Prostate cancer is one of the most common male cancer. Over 1.1 million cases are diagnosed each year. To confirm the diagnosis, a biopsy sample is needed. The sample is later analyzed by a pathologist. The AI-system is capable of taking good care of the diagnosis process.
The research results reveal an accuracy of 99.38%. That is as high as a human pathologist. Guo added, "The machine was programmed to learn and gradually improve the way that it comprehended the samples. Our result shows that the diagnosis the AI reported was at a level akin to that of a pathologist. Additionally, it may accurately classify the cancerous heights of prostate cancer"